Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)

This study has been completed.
Information provided by (Responsible Party):
TRB Chemedica Identifier:
First received: June 28, 2010
Last updated: April 8, 2014
Last verified: April 2014

To evaluate the efficacy of Diacerein 100 mg daily versus placebo in reducing rheumatoid arthritis symptoms, when added to stable oral MTX therapy in patients with active early RA.

To evaluate the safety of Diacerein 100 mg daily when administrated in combination with oral MTX therapy in those patients for up to 24 weeks

To investigate a potential persistent effect, 4 weeks after Diacerein treatment is stopped (carry-over effect)

Condition Intervention Phase
Rheumatoid Arthritis
Drug: Diacerein
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study

Resource links provided by NLM:

Further study details as provided by TRB Chemedica:

Primary Outcome Measures:
  • Percentage of patients with ACR20 response criteria [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Percentage of patients achieving a moderate response according to EULAR response criteria (changes in DAS28 score) [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: October 2010
Study Completion Date: April 2014
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Diacerein Drug: Diacerein
Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
Placebo Comparator: Placebo


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female aged between 18 and 65 years;
  2. Active RA of ≥ 3 months duration but < 2 years, diagnosed according to the American College of Rheumatology (ACR) 1987 revised criteria for RA;
  3. RA global functional status class I-III;
  4. Treatment on an outpatient basis;
  5. Treatment with MTX for a minimum of 12 weeks, with stable weekly dose (10-20 mg) for at least 4 weeks before randomisation;
  6. Insufficient response to treatment with MTX, with disease activity score DAS28 > 4.0 at the time of screening and randomisation; the DAS28 must not change significantly from screening to baseline visit (change < 0.6);
  7. Tender joint count (TJC) ≥ 6 (68 joint count) and swollen joint count (SJC) ≥ 6 (66 joint count) at screening and randomisation;
  8. Screening ESR ≥ 28 mm/h;
  9. Evidence of adequate contraceptive methods in women of childbearing potential. Female patients of childbearing potential are those who are not surgically sterile or post-menopausal. Adequate contraceptive methods are hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the entire duration of the study;
  10. Agreement not to drink alcohol for the duration of the study;
  11. Ability and agreement to comply with the requirements of the study protocol;
  12. Having given written informed consent to participate in the study.

Exclusion Criteria:

  1. History of active inflammatory arthritis other than RA;
  2. Any uncontrolled medical condition such as diabetes mellitus, asthma, cardiopulmonary disease, congestive heart failure, neurological disease, etc.;
  3. Alcohol abuse, defined as the consumption of more than one glass of beer or wine in a day;
  4. Moderate or severe liver disease (cirrhosis, hepatitis, liver insufficiency);
  5. Blood anomalies (significant cytopenia);
  6. History of, or currently active primary or secondary immunodeficiency;
  7. Chronic hepatitis B (HBsAg positive or HBcAb positive with HBV DNA load ≥ 400 copies/ml) or hepatitis C (anti-HCV positive);
  8. Current known active, or history of, recurrent bacterial, viral, fungal, mycobacterial or other infections, or any infection requiring hospitalisation or treatment with i.v. antibiotics within 4 weeks prior to randomisation or oral antibiotics within 2 weeks prior to randomisation;
  9. Treatment with biologic DMARDs such as TNF antagonists, IL 1 receptor antagonists, IL 6 receptor antagonists, CTLA4Ig within 12 weeks prior to randomisation, and rituximab within 24 weeks prior to randomisation;
  10. Treatment with non-biologic DMARDs such as chloroquine, hydroxychloroquine, penicillamine, sulfasalazine within 4 weeks prior to randomisation, leflunomide, parenteral gold, oral gold within 8 weeks prior to randomisation, azathioprine and ciclosporin within 12 weeks prior to randomisation;
  11. Treatment with intra-articular injection of a depocorticosteroid within 8 weeks prior to randomisation;
  12. Treatment with NSAID or oral corticosteroids, unless the patient has been on a stable dose for at least 4 weeks before randomisation (maximal allowed daily dose of oral corticosteroid equivalent to prednisone 10 mg);
  13. Physical therapy and alternative therapies, unless the patient has received them regularly for at least 4 weeks before randomisation;
  14. Initiation of chronic treatment with antihistaminics, antidepressants or tranquilisers, within less than 12 weeks before randomisation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01264211

Juree Rawdmanee
Sukhumvit, Bangkok, Thailand, 10110
Faculty of medicine, Chiangmai University
Chiangmai, Thailand, 50002
Sponsors and Collaborators
TRB Chemedica
  More Information

No publications provided

Responsible Party: TRB Chemedica Identifier: NCT01264211     History of Changes
Other Study ID Numbers: DAR-THA-05-01
Study First Received: June 28, 2010
Last Updated: April 8, 2014
Health Authority: Thailand: Ethical Committee

Keywords provided by TRB Chemedica:
Efficacy of Diacerein
Safety of Diacerein
Carry-over effect of Diacerein

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents
Pharmacologic Actions
Therapeutic Uses processed this record on November 25, 2014